Seres Therapeutics Inc Revenue Growth Rates (MCRB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Seres Therapeutics Inc   (NASDAQ: MCRB)
 

MCRB's Revenue Growth by Quarter and Year

Seres Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MCRB/growth
https://api.csimarket.com/api/v1/companies/MCRB/fundamentals
https://api.csimarket.com/api/v1/companies/MCRB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MCRB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.59
2nd Quarter June 0.74
1st Quarter March 0.36
FY 1.69

MCRBs Annual Revenue
Seres Therapeutics Inc 's Revenue in the fiscal year 2025 $ 0.79 millions
Seres Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.00 millions
Seres Therapeutics Inc 's Revenue in the fiscal year 2023 $ 126.33 millions
Seres Therapeutics Inc 's Revenue in the fiscal year 2022 $ 7.13 millions
Seres Therapeutics Inc 's Revenue in the fiscal year 2021 $ 144.93 millions




MCRB Revenue third quarter 2026 Y/Y Growth Comment
Seres Therapeutics Inc reported Revenue surge of 69.43% year on year in the third quarter 2026, to $ 0.59 millions, this is lower than Seres Therapeutics Inc 's recent average Revenue surge of 122.33%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue growth. While Seres Therapeutics Inc ' s Revenue jump of 69.43% ranks overall at the positon no. 133 in the third quarter 2026.


MCRB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 69.43 %
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Seres Therapeutics Inc 's third quarter 2026 Revenue $ 0.59 millions MCRB's Income Statement
Seres Therapeutics Inc 's third quarter 2025 Revenue $ 0.35 millions Quarterly MCRB's Income Statement


MCRB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -19.86 %
2nd Quarter June 105.56 %
1st Quarter March -18.18 %
FY (Year on Year)   -


Back to MCRB Growth rate Comparisons >> Back to MCRB Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #43
Overall #133

Revenue Y/Y Growth Statistics
High Average Low
2307.85 % 122.33 % -100 %
(Sep 30 2021)   (Mar 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #43
Overall #133
Revenue Y/Y Growth Statistics
High Average Low
2307.85 % 122.33 % -100 %
(Sep 30 2021)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Seres Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2307.85 % 118.16 % -100 %
(Sep 30 2021)  


MCRB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Seres Therapeutics Inc disclosed fall in Revenue from the second quarter by -19.86% to $ 0.59 millions, from $ 0.74 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Seres Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3349.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #161
Healthcare Sector #459
Overall #3349
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #161
Healthcare Sector #459
Overall #3349
Revenue Q/Q Growth Statistics
High Average Low
2307.85 % 118.16 % -100 %
(Sep 30 2021)  


MCRB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Seres Therapeutics Inc disclosed fall in Revenue from the second quarter by -19.86% to $ 0.59 millions, from $ 0.74 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Seres Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3349.


Seres Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1.88
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
Seres Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 69.43% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026.
Seres Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Seres Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.

Seres Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
Seres Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 69.43% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026.
Seres Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Seres Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.

Seres Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MCRB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions


About Seres Therapeutics Inc Revenue Growth Rates (MCRB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Seres Therapeutics Inc (CIK 1609809).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-446427
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Seres Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.